Trials / Terminated
TerminatedNCT04131192
Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
A Phase Ib, Multi-center, Open-label Study of Z650 and Gemcitabine in Advanced Pancreatic Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Sunshine Lake Pharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This phase IB trial is studying how well giving gemcitabine together with Z650 works in treating patients with metastatic or recurrent pancreatic cancer.
Detailed description
This phase IB trial is studying how well giving gemcitabine together with Z650 works in treating patients with metastatic or recurrent pancreatic cancer.This phase IB trial is Multi-center and open。
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Z650 | 250 or 300 or 200 mg/d, starting on the 2nd day, once a day, continuous administration, or about half an hour after a meal |
| DRUG | Gemcitabine | Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, of a 21-day cycle ，for 4-6 cycles |
Timeline
- Start date
- 2019-11-11
- Primary completion
- 2021-09-09
- Completion
- 2021-09-09
- First posted
- 2019-10-18
- Last updated
- 2022-05-06
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04131192. Inclusion in this directory is not an endorsement.